GLUD1 and cancer: Even though many cancer cells rely on GLUD1-mediated Glut deamination to replenish the Krebs cycle, epigallocatechin gallate (EGCG) (50 μM), a GLUD1 inhibitor, had surprisingly no effect on ChREBP-mediated proliferation of SNU449 and SNU475 cells (Fig. 8e and Supplementary Fig. 11j).